Albemarle Corp (ALB) stock

ALBNYSEPlastic Materials, Synth Resins & Nonvulcan ElastomersFiscal year ends December 31Also trades as ALB.PA

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 16/3022% below fair value

$91.00−2.27 (-2.43%)

Close on Oct 30, 2026Market cap $10.74BP/E 337.0Yield 1.78%

Earnings

Albemarle's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Nov 4, 2026

Q3 FY2026 · estimated, after the close

Revenue, Q2 FY2026

$1.74B

+34.1% on a year earlier

Adjusted diluted income per share attributable to common shareholders, Q2 FY2026

$3.75

$0.11 a year earlier

Latest guidance

Raised

Aug 5, 2026 · 7 items

Quarterly results

Revenue and earnings per share from each of Albemarle's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q3 FY2026ended Sep 30, 2026	Nov 4, 2026Expected	–	–	–	–	–
Q2 FY2026ended Jun 30, 2026	Aug 5, 2026after the close	$1.74B	+34.1%	$3.52	$3.75	Release
Q1 FY2026ended Mar 31, 2026	May 6, 2026after the close	$1.43B	+29.9%	$2.34	$2.95	Release
Q4 FY2025ended Dec 31, 2025	Feb 11, 2026after the close	$1.40B	+16.7%	-$3.87	-$0.53	Release
Q3 FY2025ended Sep 30, 2025	Nov 5, 2025after the close	$1.30B	-7.1%	-$1.72	-$0.19	Release
Q2 FY2025ended Jun 30, 2025	Jul 30, 2025after the close	$1.30B	-7.1%	-$0.16	$0.11	Release
Q1 FY2025ended Mar 31, 2025	Apr 30, 2025after the close	$1.10B	-21.4%	$0.00	-$0.18	Release
Q4 FY2024ended Dec 31, 2024	Feb 12, 2025after the close	$1.20B	-50.0%	$0.29	-$1.09	Release
Q3 FY2024ended Sep 30, 2024	Nov 6, 2024after the close	$1.40B	-39.1%	–	-$1.55	Release
Q2 FY2024ended Jun 30, 2024	Jul 31, 2024after the close	$1.40B	-41.7%	-$1.96	$0.04	Release
Q1 FY2024ended Mar 31, 2024	May 1, 2024after the close	$1.40B	-46.2%	-$0.08	$0.26	Release
Q4 FY2023ended Dec 31, 2023	Feb 14, 2024after the close	$2.40B	–	-$5.26	-$5.19	Release
Q3 FY2023ended Sep 30, 2023	Nov 1, 2023after the close	$2.30B	+9.5%	$2.57	$2.74	Release
Q2 FY2023ended Jun 30, 2023	Aug 2, 2023after the close	$2.40B	+62.2%	$5.52	$7.33	Release
Q1 FY2023ended Mar 31, 2023	May 3, 2023after the close	$2.60B	+130.1%	$10.51	$10.32	Release
Q4 FY2022ended Dec 31, 2022	Jan 24, 2023after the close	–	–	–	–	Release
Q3 FY2022ended Sep 30, 2022	Nov 2, 2022after the close	$2.10B	+152.8%	$7.61	$7.50	Release
Q2 FY2022ended Jun 30, 2022	Aug 3, 2022after the close	$1.48B	–	$3.46	$3.45	Release
Q1 FY2022ended Mar 31, 2022	May 4, 2022after the close	$1.13B	–	$2.15	$2.38	Release
Q4 FY2021ended Dec 31, 2021	Feb 16, 2022after the close	$894.20M	–	-$0.03	$1.01	Release
Q3 FY2021ended Sep 30, 2021	Nov 3, 2021after the close	$830.60M	–	-$3.36	$1.05	Release
Q2 FY2021ended Jun 30, 2021	Aug 4, 2021after the close	–	–	–	–	Filing
Q1 FY2021ended Mar 31, 2021	May 5, 2021after the close	–	–	–	–	Release
Q4 FY2020ended Dec 31, 2020	Feb 2, 2021after the close	–	–	–	–	Filing
Q3 FY2020ended Sep 30, 2020	Nov 4, 2020after the close	–	–	–	–	Filing
Q2 FY2020ended Jun 30, 2020	Aug 5, 2020after the close	–	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Albemarle's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
Specialties net sales	FY2026	$1.40B – $1.60B	$1.30B – $1.50B	Raised	Aug 5, 2026
Specialties adjusted EBITDAnon-GAAP	FY2026	$275.00M – $325.00M	$225.00M – $275.00M	Raised	Aug 5, 2026
Capital expenditures	FY2026	$500.00M	$550.00M – $600.00M	Lowered	Aug 5, 2026
Adjusted effective tax ratenon-GAAP	FY2026	-50% – 30%	-50% – 30%	Reaffirmed	Aug 5, 2026
Depreciation and amortization	FY2026	$660.00M – $680.00M	$660.00M – $680.00M	Reaffirmed	Aug 5, 2026
Interest and financing expense	FY2026	$120.00M – $140.00M	–	Lowered	May 6, 2026
Interest and financing expenses	FY2026	$120.00M – $140.00M	$150.00M – $170.00M	Lowered	Aug 5, 2026
Net sales (5-Year CAGR)GAAP	FY2027	+19% – +21%	–	New	Jan 23, 2023
Adj. EBITDA (2027E)non-GAAP	FY2027	$7.20B – $8.40B	–	New	Jan 23, 2023
Free Cash Flow (2027E)non-GAAP	FY2027	$2.60B – $2.70B	–	New	Jan 23, 2023
Adj. EBITDA Margin (2027E)non-GAAP	FY2027	41% – 44%	–	New	Jan 23, 2023

Guidance history

Every forecast Albemarle put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Aug 5, 2026	Capital expenditures	FY2026	$500.00M	Lowered
Aug 5, 2026	Specialties adjusted EBITDA	FY2026	$275.00M – $325.00M	Raised
Aug 5, 2026	Corporate adjusted EBITDA (incl. FX, Ketjen equity income & PCS)	FY2026	-$20.00M – $20.00M	Lowered
Aug 5, 2026	Adjusted effective tax rate	FY2026	-50% – 30%	Reaffirmed
Aug 5, 2026	Depreciation and amortization	FY2026	$660.00M – $680.00M	Reaffirmed
Aug 5, 2026	Interest and financing expenses	FY2026	$120.00M – $140.00M	Lowered
Aug 5, 2026	Specialties net sales	FY2026	$1.40B – $1.60B	Raised
May 6, 2026	Capital expenditures	FY2026	$550.00M – $600.00M	Reaffirmed
May 6, 2026	Specialties adjusted EBITDA	FY2026	$225.00M – $275.00M	Raised
May 6, 2026	Corporate adjusted EBITDA	FY2026	-$20.00M – $20.00M	Lowered
May 6, 2026	Adjusted effective tax rate	FY2026	-50% – 30%	Reaffirmed
May 6, 2026	Interest and financing expense	FY2026	$120.00M – $140.00M	Lowered
May 6, 2026	Depreciation and amortization	FY2026	$660.00M – $680.00M	Raised
May 6, 2026	Specialties net sales	FY2026	$1.30B – $1.50B	Raised
Feb 11, 2026	Capital expenditures	FY2026	$550.00M – $600.00M	New
Feb 11, 2026	Corporate adjusted EBITDA (incl. FX, Ketjen equity income & PCS)	FY2026	-$20.00M – $20.00M	New
Feb 11, 2026	Specialties adjusted EBITDA	FY2026	$170.00M – $230.00M	Raised
Feb 11, 2026	Adjusted effective tax rate	FY2026	-50% – 30%	New
Feb 11, 2026	Interest and financing expenses	FY2026	$150.00M – $170.00M	New
Feb 11, 2026	Depreciation and amortization	FY2026	$660.00M – $680.00M	Raised
Feb 11, 2026	Specialties net sales	FY2026	$1.20B – $1.40B	New
Nov 5, 2025	capital expenditures	FY2025	$600.00M	New
Nov 5, 2025	free cash flow	FY2025	$300.00M – $400.00M	New
Jul 30, 2025	Capital expenditures	FY2025	$650.00M – $700.00M	Lowered
Jul 30, 2025	Adjusted EBITDA	FY2025	$800.00M – $1.00B	Raised
Jul 30, 2025	Adjusted EBITDA	FY2025	$600.00M – $700.00M	Lowered
Jul 30, 2025	Specialties adjusted EBITDA	FY2025	$210.00M – $280.00M	Lowered
Jul 30, 2025	Ketjen adjusted EBITDA	FY2025	$120.00M – $150.00M	Lowered
Jul 30, 2025	Weighted-average common shares outstanding (diluted)	FY2025	118	Reaffirmed
Jul 30, 2025	Adjusted effective tax rate	FY2025	-40% – 25%	Reaffirmed
Jul 30, 2025	Equity in net income of unconsolidated investments (net of tax)	FY2025	$200.00M – $300.00M	Raised
Jul 30, 2025	Depreciation and amortization	FY2025	$630.00M – $670.00M	Raised
Jul 30, 2025	Corporate costs	FY2025	$40.00M – $70.00M	Lowered
Jul 30, 2025	Interest and financing expenses	FY2025	$180.00M – $210.00M	Raised
Jul 30, 2025	Net sales	FY2025	$4.90B – $5.20B	Raised
Jul 30, 2025	Net sales	FY2025	$2.50B – $2.60B	Lowered
Jul 30, 2025	Specialties net sales	FY2025	$1.30B – $1.50B	Lowered
Jul 30, 2025	Ketjen net sales	FY2025	$1.00B – $1.10B	Lowered
Apr 30, 2025	capital expenditures	FY2025	$700.00M – $800.00M	Reaffirmed
Apr 30, 2025	Adjusted effective tax rate	FY2025	-40% – 25%	Reaffirmed
Feb 12, 2025	capital expenditures	FY2025	$700.00M – $800.00M	Lowered
Feb 12, 2025	Specialties adjusted EBITDA	FY2025	$210.00M – $280.00M	New
Feb 12, 2025	Ketjen adjusted EBITDA	FY2025	$120.00M – $150.00M	Lowered
Feb 12, 2025	Weighted-average common shares outstanding (diluted)	FY2025	118	New
Feb 12, 2025	Adjusted effective tax rate	FY2025	-40% – 25%	New
Feb 12, 2025	projected increase in Energy Storage volumes	FY2025	0% – +10%	New
Feb 12, 2025	Depreciation and amortization	FY2025	$630.00M – $670.00M	New
Feb 12, 2025	Corporate costs	FY2025	$70.00M – $100.00M	Lowered
Feb 12, 2025	Interest and financing expenses	FY2025	$180.00M – $210.00M	Raised
Feb 12, 2025	Specialties net sales	FY2025	$1.30B – $1.50B	New
Feb 12, 2025	Ketjen net sales	FY2025	$1.00B – $1.10B	Lowered
Nov 6, 2024	Capital expenditures	FY2024	$1.70B – $1.80B	Reaffirmed
Nov 6, 2024	capital expenditures	FY2025	$800.00M – $900.00M	New
Nov 6, 2024	Adjusted EBITDA	FY2024	$900.00M – $1.20B	Reaffirmed
Nov 6, 2024	Net sales	FY2024	$5.50B – $6.20B	Reaffirmed
Jul 31, 2024	Capital expenditures	FY2024	$1.70B – $1.80B	Raised
Jul 31, 2024	Adjusted EBITDA	FY2024	$900.00M – $1.20B	Lowered
Jul 31, 2024	charge	Q3 FY2024	$900.00M – $1.10B	New
Jul 31, 2024	Depreciation and amortization	FY2024	$580.00M – $630.00M	Raised
Jul 31, 2024	Corporate costs (excluding FX)	FY2024	$60.00M – $90.00M	Lowered
Jul 31, 2024	Interest and financing expenses	FY2024	$140.00M – $170.00M	Raised
Jul 31, 2024	Specialties adj. EBITDA	FY2024	$210.00M – $260.00M	New
Jul 31, 2024	Net sales	FY2024	$5.50B – $6.20B	Lowered
May 1, 2024	Capital expenditures	FY2024	$1.60B – $1.80B	Reaffirmed
May 1, 2024	Adjusted EBITDA	FY2024	$900.00M – $2.60B	Reaffirmed
May 1, 2024	Weighted-average common shares outstanding (diluted)	FY2024	135 – 139	New
May 1, 2024	Adjusted effective tax rate	FY2024	-5% – 27%	New
May 1, 2024	Depreciation and amortization	FY2024	$580.00M – $660.00M	New
May 1, 2024	Corporate costs	FY2024	$120.00M – $150.00M	Lowered
May 1, 2024	Interest and financing expenses	FY2024	$180.00M – $210.00M	Raised
May 1, 2024	Net sales	FY2024	$5.50B – $7.60B	New
Feb 14, 2024	capital expenditures	FY2024	$1.60B – $1.80B	New
Feb 14, 2024	Adjusted EBITDA	FY2024	$900.00M – $2.60B	New
Feb 14, 2024	Net sales	FY2024	$5.50B – $7.60B	New
Nov 1, 2023	Capital Expenditures	FY2023	$1.90B – $2.10B	Reaffirmed
Nov 1, 2023	Adjusted EBITDA	FY2023	$3.20B – $3.40B	Lowered
Nov 1, 2023	Adjusted Diluted EPS	FY2023	$21.50 – $23.50	Lowered
Nov 1, 2023	Adjusted EBITDA Margin	FY2023	34% – 35%	Lowered
Nov 1, 2023	Net Cash from Operations	FY2023	$600.00M – $800.00M	Lowered
Nov 1, 2023	Net sales	FY2023	$9.50B – $9.80B	Lowered
Aug 2, 2023	Capital Expenditures	FY2023	$1.90B – $2.10B	Raised
Aug 2, 2023	Adjusted EBITDA	FY2023	$3.80B – $4.40B	Raised
Aug 2, 2023	Adjusted Diluted EPS	FY2023	$25.00 – $29.50	Raised
Aug 2, 2023	Adjusted EBITDA Margin	FY2023	37% – 38%	Raised
Aug 2, 2023	Net Cash from Operations	FY2023	$1.20B – $1.80B	Lowered
Aug 2, 2023	Net sales	FY2023	$10.40B – $11.50B	Raised
May 3, 2023	Capital Expenditures	FY2023	$1.70B – $1.90B	New
May 3, 2023	Adjusted EBITDA	FY2023	$3.30B – $4.00B	Lowered
May 3, 2023	Adjusted Diluted EPS	FY2023	$20.75 – $25.75	Lowered
May 3, 2023	Adjusted EBITDA Margin	FY2023	34% – 35%	Lowered
May 3, 2023	Net Cash from Operations	FY2023	$1.70B – $2.30B	New
May 3, 2023	Net sales	FY2023	$9.80B – $11.50B	New
Jan 23, 2023	Capital Expenditures	FY2023	$1.70B – $1.90B	New
Jan 23, 2023	Adj. EBITDA (2027E)	FY2027	$7.20B – $8.40B	New
Jan 23, 2023	Adjusted EBITDA	FY2023	$4.20B – $5.10B	New
Jan 23, 2023	Adjusted Diluted EPS	FY2023	$26.00 – $33.00	New
Jan 23, 2023	Free Cash Flow (2027E)	FY2027	$2.60B – $2.70B	New
Jan 23, 2023	Adjusted EBITDA Margin	FY2023	37% – 40%	New
Jan 23, 2023	Net Cash from Operations	FY2023	$2.10B – $2.40B	New
Jan 23, 2023	Adj. EBITDA Margin (2027E)	FY2027	41% – 44%	New
Jan 23, 2023	Net sales	FY2023	$11.30B – $12.90B	New
Jan 23, 2023	Net sales (5-Year CAGR)	FY2027	+19% – +21%	New
Nov 2, 2022	Capital Expenditures	FY2022	$1.30B – $1.40B	Lowered
Nov 2, 2022	Adjusted EBITDA	FY2022	$3.30B – $3.50B	Raised
Nov 2, 2022	Adjusted Diluted EPS	FY2022	$19.75 – $21.75	Narrowed
Nov 2, 2022	Adjusted EBITDA Margin	FY2022	46% – 47%	Raised
Nov 2, 2022	Net Cash from Operations	FY2022	$1.45B – $1.65B	Narrowed
Nov 2, 2022	Net sales	FY2022	$7.10B – $7.40B	Lowered
Aug 3, 2022	Capital Expenditures	FY2022	$1.30B – $1.50B	Reaffirmed
Aug 3, 2022	Adjusted EBITDA	FY2022	$3.20B – $3.50B	Raised
Aug 3, 2022	Adjusted Diluted EPS	FY2022	$19.25 – $22.25	Raised
Aug 3, 2022	Adjusted EBITDA Margin	FY2022	45% – 47%	Raised
Aug 3, 2022	Net Cash from Operations	FY2022	$1.40B – $1.70B	Raised
Aug 3, 2022	Net sales	FY2022	$7.10B – $7.50B	Raised
May 4, 2022	Capital Expenditures	FY2022	$1.30B – $1.50B	New
May 4, 2022	Adjusted EBITDA	FY2022	$1.70B – $2.00B	Raised
May 4, 2022	Adjusted Diluted EPS	FY2022	$9.25 – $12.25	Raised
May 4, 2022	Adjusted EBITDA Margin	FY2022	33% – 36%	Raised
May 4, 2022	Net Cash from Operations	FY2022	$500.00M – $800.00M	Raised
May 4, 2022	Net sales	FY2022	$5.20B – $5.60B	Raised
Feb 16, 2022	Capital Expenditures	FY2022	$1.30B – $1.50B	New
Feb 16, 2022	Adjusted EBITDA	FY2022	$1.15B – $1.30B	New
Feb 16, 2022	Adjusted Diluted EPS	FY2022	$5.65 – $6.65	New
Feb 16, 2022	Adjusted EBITDA Margin	FY2022	27% – 29%	New
Feb 16, 2022	Net Cash from Operations	FY2022	$400.00M – $500.00M	New
Feb 16, 2022	Net sales	FY2022	$4.20B – $4.50B	New
Nov 3, 2021	Capital Expenditures	FY2021	$925.00M – $975.00M	New
Nov 3, 2021	Adjusted EBITDA	FY2021	$830.00M – $860.00M	New
Nov 3, 2021	Adjusted Diluted EPS	FY2021	$3.85 – $4.15	New
Nov 3, 2021	Adjusted EBITDA Margin	FY2021	25%	New
Nov 3, 2021	Net Cash from Operations	FY2021	$550.00M – $650.00M	New
Nov 3, 2021	Net sales	FY2021	$3.30B – $3.40B	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.